3/29/2011

Cephalon has agreed to pay about $231 million in cash to acquire ChemGenex Pharmaceuticals, an Australian biotech firm that is seeking marketing approval from the FDA for its drug candidate for chronic myeloid leukemia. The companies said ChemGenex directors unanimously support Cephalon's offer.

Full Story:
Reuters

Related Summaries